Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
To compare the impact of liberal vs conservative oxygen doses on markers of oxidative stress in patients enrolled in the BLENDER trial.
Extracorporeal membrane oxygen (ECMO) is a heart lung support device used for patients with severe and cardiac and respiratory failure and carries an increased risk of exposure to very high oxygen tensions. Hyperoxia (arterial oxygen >100mmHg) can lead to the production of reactive oxygen species (ROS). Excess production of ROS and depletion of antioxidant compounds is referred to as oxidative stress and results in inflammation, tissue injury and cell death. The inter-relationship between the production of ROS and end organ dysfunction is complicated and remain unclear. A more detailed assessment of the timing of changes in markers of oxidative stress, inflammatory mediators and tissue injury is warranted to understand the processes and potentially identify therapeutic targets.
The BLENDER Trial is a multicentre trial in ECMO patients to determine whether a conservative oxygen strategy during ECMO reduces ICU length of stay and improves patient outcomes compared to a liberal oxygen strategy. Currently there have been no studies that look at the underlying pathophysiological changes that occur in patients on ECMO when subjected to different oxygen concentrations. As such The BLENDER study represents a unique opportunity to understand the mechanisms by which hyperoxia may cause tissue injury in patients receiving ECMO. This nested study seeks to elucidate whether exposure to hyperoxia during ECMO results in increased oxidative stress and whether this is correlated with increased risk of tissue injury and organ dysfunction. A better understanding of the mechanism of hyperoxia induced tissue injury may allow treatment to be optimised for patients exposed to hyperoxia as part of their treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Super oxide dismutase levels U/ml | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO | Within 24 hours of ECMO commencement |
| Measure | Description | Time Frame |
|---|---|---|
| Marker of Cardiac Injury | Troponin ng/ml This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 3 of ECMO |
| Marker of Cardiac Injury | Troponin I ng/ml This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO |
| Measure | Description | Time Frame |
|---|---|---|
| Marker of Fibrinolysis | Fibrinogen, Plasmin anti-plasmin complex, D-Dimer This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 3 of ECMO |
| Marker of Fibrinolysis |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
VA-ECMO patients enrolled in the BLENDER trial
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Alfred Hospital | Melbourne | Victoria | 3004 | Australia |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D006333 | Heart Failure |
| D016638 | Critical Illness |
| D018496 | Hyperoxia |
| ID | Term |
|---|---|
| D006331 | Heart Diseases |
| D002318 | Cardiovascular Diseases |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
Not provided
Not provided
Not provided
Not provided
Not provided
| Day 7 of ECMO |
| Markers of Liver Injury | ALT and AST (IU/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 3 of ECMO |
| Markers of Liver Injury | ALT and AST (IU/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 7 of ECMO |
| Marker of Neurological Injury | Neuron Specific Enolase (microg/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 3 of ECMO |
| Marker of Neurological Injury | Neuron Specific Enolase (microg/L) This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 7 of ECMO |
| Coagulation Parameters | APTT This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 3 of ECMO |
| Coagulation Parameters | APTT This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO | Day 7 of ECMO |
| Immune Markers | IL-6, TNFa, IL-10, IL-1B (pg/ml) | Day 3 of ECMO |
| Immune Markers | IL-6, TNFa, IL-10, IL-1B (pg/ml) | Day 7 of ECMO |
| Other Markers of Oxidative Stress | Malondialdehyde, Vitamin C | Day 3 of ECMO |
| Other Markers of Oxidative Stress | Malondialdehyde, Vitamin C | Day 7 of ECMO |
| Superoxide dismutase levels U/ml | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO | On Day 3 following ECMO commencement |
| Superoxide dismutase levels | Plasma levels of superoxide dismutase in patients exposed to either a liberal or conservative oxygen strategy during VA-ECMO | On Day 7 following ECMO commencement |
| Markers of Kidney Injury | Creatinine (micromol/L) | Day 3 of ECMO |
| Markers of Kidney Injury | Creatinine (micromol/L) | Day 7 of ECMO |
Fibrinogen, Plasmin anti-plasmin complex, D-dimer
This will be determined by analysing blood samples routinely collected daily from patient receiving ECMO
| Day 7 of ECMO |
| D013568 |
| Pathological Conditions, Signs and Symptoms |
| D012818 | Signs and Symptoms, Respiratory |
| D012816 | Signs and Symptoms |